Our previous studies have demonstrated that arsenic trioxide (ATO) had the clinical efficacy in treating patients with aplastic anemia (AA). However, the mechanisms remain to be elucidated. The important components of the bone marrow hematopoietic microenvironment, bone marrow mesenchymal stem cells (BMSCs), are often altered in AA patients. In this study, it was found that AA BMSCs were prone to be induced into adipocytes rather than osteoblasts. ATO treatment can at least partially restore the differentiation imbalance of AA BMSCs. We further identified miR-204 as a key regulator in AA BMSC differentiation. Luciferase reporter assay showed that miR-204 could directly bind to the 3 0 -untranslated region of Runx2 mRNA, a key transcription factor regulating osteogenesis. Moreover, adipogenic differentiation was promoted and osteogenic differentiation was inhibited in miR-204 over-expressed cells, whereas osteogenesis was enhanced and adipocyte formation was inhibited in cells that lost miR-204 function, which suggested its endogenous function. Together we showed that ATO could inhibit adipogenic differentiation, but promote osteogenic differentiation in AA BMSCs, providing a possible explanation for ATO clinical efficacy in AA patients. MiR-204 plays a key role in regulating BMSCs differentiation, and down-regulating miR-204 expression might be a novel strategy to treat AA.
Introduction
Aplastic anemia (AA) is a complex bone marrow failure syndrome characterized by an extremely hypocellular marrow and peripheral blood pancytopenia. Its pathophysiology is not completely clear. The possible pathogenic causes include reduced hematopoietic stem cells (HSCs) number [1] , impaired HSC function [2] , increased bone marrow cellular apoptosis level [3] , and altered bone marrow hematopoietic microenvironment [4] .
Mesenchymal stem cells are important components of the bone marrow hematopoietic microenvironment. MSCs have the ability to self-renew and to differentiate into cells of different lineages, including osteocytes, adipocytes, chondrocytes, reticular fibroblasts, macrophages, and endothelial cells, both in vivo and in vitro [5] . It is known that the osteogenic and adipogenic differentiations of MSCs are well balanced in the normal bone marrow. The imbalance of osteogenic and adipogenic differentiations of MSCs will lead to diseases [6, 7] . Interestingly, it was observed that the number of adipocytes increased, while the osteoblasts decreased in the bone marrow of patients with AA. Supporting the role of osteoblast in HSC function, Zhang et al. [8] showed that spindle-shaped N-cadherinþCD45-osteoblastic (SNO) cells lining the bone surface functioned as a major component of the niche to support HSCs, the reduction of which would affect the normal hematopoiesis. Therefore, maintaining the correct balance of osteogenic and adipogenic differentiations from MSCs might be a useful strategy for AA treatment.
Arsenic trioxide (ATO), an anti-tumor drug, induces cancer cell differentiation at low doses and accelerates apoptosis or autophagic cell death at high doses [9] . It was shown that ATO could restore the expression levels of tumor suppressor genes in hematologic malignant cells through causing promoter demethylation along with an inhibition of DNA methyltransferases 1, 3a, and 3b [10] . Cheng et al. [11] reported that 1 mM ATO could promote MSC senescence mainly through p21 signaling pathway. Furthermore, ATO can inhibit adipogenic differentiation, while promoting osteogenic differentiation in normal bone marrow mesenchymal stem cells (BMSCs), likely by regulating CCAAT/ enhancer-binding protein alpha (C/EBPa) and peroxisome proliferator-activated receptor gamma (PPARg). Intriguingly, our previous clinical studies have demonstrated that patients achieved clinically exciting responses to ATO [12, 13] . However, the mechanism is still unclear.
MicroRNAs (miRNAs) are single-stranded RNA molecules with 20 25 nucleotides, expressed in a tissue and cell type specific manner. They play essential roles in many biological processes including development, organ morphology, cell proliferation, signaling and apoptosis [14] through partially binding to 3 0 -untranslated region (UTR) of target mRNAs, which causes mRNA destabilization or translation inhibition [15] . Recent studies have revealed the critical role of a class of stem-cell specific miRNAs in regulating stem cell self-renewal and differentiation [16] . Another set of studies have identified several miRNAs regulating MSCs differentiation [17] [18] [19] . Among these, miR-204 was demonstrated to be significantly down-regulated in a broad range of tumors [20] . Huang et al. [17] showed that miR-204 promoted adipogenesis and inhibited the osteoblastic differentiation of mesenchymal progenitor cells and BMSCs by down-regulating the key transcription factor Runx2, an important factor in osteogenesis. However, it is unknown whether miR-204 exerts any effect on AA BMSCs.
In this study, we aimed to compare the characteristics of AA BMSCs with normal BMSCs, investigate the function of ATO in regulating AA BMSCs differentiation, and explore the role of miR-204 in the regulating adipogenic and osteogenic differentiation of AA BMSCs.
Materials and Methods
Specimens collection BM cells were obtained from iliac crest aspirates. Control subjects (n ¼ 7) were patients who received BM examination for diseases other than hematological diseases with pathological proof of normal BM. All patients were previously untreated with the age no less than 18 years old. AA was diagnosed by pancytopenia and hypocellular BM after excluding other underlying diseases (n ¼ 6). The study was approved by the Institutional Review Board at Henan Tumor Hospital. All patients signed an informed consent.
BMSC isolation and culture
Mononuclear cells were isolated from BM aspirates by Ficoll-Paque density gradient centrifugation (1.077 g/ml; Amersham Biosciences, Buckinghamshire, UK) and then seeded in Dulbecco's modified Eagle medium/F12 (DMEM/ F12; Gibco, Carlsbad, USA) supplemented with 10% fetal bovine serum (FBS; Gibco) and 1% antibiotic-antimycotic (Gibco). Cells were incubated at 378C with 5% CO 2 in a humidified atmosphere. After 72 h, the medium with suspension of non-adherent cells was discarded, and fresh medium was added. Thereafter, the medium was replaced every 3 days. Then the cells were reseeded at a dilution of 1 : 2 when the cells reached 80%-90% confluency.
Immunophenotypic analysis Cultured MSCs were detached, washed, and resuspended in phosphate buffered saline (PBS; Gibco). After fixing and blocking, the cells were immunolabeled with the following mouse anti-human antibodies: fluorescein isothiocyanateconjugated CD45 (FITC-CD45; BD Biosciences, San Jose, USA), FITC-CD34 (BD Biosciences), FITC-C D105 (Serotec, Oxford, UK), PE-CD73 (BD Pharmigen, San Diego, USA), and FITC-CD44 (BD Pharmigen). The nonspecific mouse IgG (BD Biosciences) served as isotype control. Cells were sorted by flow cytometry (FACSCalibur; BD Biosciences) and data were analyzed with CellQuest software.
In vitro differentiation MSCs (6 Â 10 5 ) at Passage 3 treated with 1 mM ATO for 48 h were plated in six-well chamber slides after washing twice with PBS, and the inducing medium was added on the next day. For promoting osteogenic differentiation, cells were incubated in DMEM supplemented with 10% FBS, 10 mM b-glycerophosphate (Sigma, St Louis, USA), 0.1 mM dexamethasone (Sigma), and 0.2 mM ascorbic acid (Sigma) for 3 weeks. After 21 days of induction, cells were stained with Alizarin Red to demonstrate osteogenic differentiation by measuring the number of mineralized nodes. Then the Alizarin red was re-dissolved in deionized water, and was semi-quantitatively analyzed at 595 nm by a plate reader. The optical density (OD) values at 595 nm represented the efficiency of osteogenic differentiation.
For the induction of adipogenic differentiation, cells were grown in DMEM supplemented with 10% FBS, 1 mM dexamethasone, 0.5 mM 3-isobutyl-1-methylxanthine (Sigma), 0.1 mM indomethacin (Sigma), and 50 mg/ml ascorbic acid for 3 weeks. After 21 days of induction, cells were stained with Oil Red O (Sigma) to demonstrate the adipogenic differentiation by intracellular accumulation of lipid droplets. Then the Oil Red O was re-dissolved in the isopropanol water, and was semi-quantitatively analyzed at 490 nm with a plate reader. The OD values at 490 nm represent the efficiency of adipogenic differentiation.
Quantitative reverse transcriptase polymerase chain reaction For mRNA, total RNA was isolated with TRIzol reagent (Invitrogen, Carlsbad, USA) according to the manufacturer's instructions. First-strand complementary DNA (cDNA) was synthesized with the RevertAid First Strand cDNA Synthesis kit (Thermo, Pittsburgh, USA). A real-time polymerase chain reaction (PCR) was performed with SYBR w Premix Ex Taq TM (Takara, Dalian, China) according to the manufacturer's instructions. The PCR protocol was as follows: 1 cycle at 958C for 1 min, 40 cycles at 958C for 15 s, 608C for 60 s. GAPDH gene was used as the internal control to calculate the relative expression.
For miRNA, total RNA was isolated using the miRNeasy Mini Kit (Qiagen, Hilden, Germany). Reverse transcription (RT) using miScript w II RT Kit (Qiagen) and quantitative PCR using miScript SYBR w PCR w Kit (Qiagen) according to the manufacturer's instructions, U6 was used as the internal control.
The signals were detected using an ABI 7300 system. The fold change of each gene was calculated from the expression levels using a 2 2DDCt method in the PCR array data analysis template provided by the manufacturer. All primer sequences and annealing temperatures are listed in Table 1 .
Western blot assay
The whole cell lysates for western blot analysis were extracted with lysis buffer containing 50 mM Tris -HCl ( pH7.6), 1 mM EDTA, 150 mM NaCl, 10% glycerol, 0.5% NP-40, and protease inhibitor cocktail. The western blot assay was carried out using a standard protocol. Fifty microgram protein of each sample was separated on 10% sodium dodecyl sulfatepolyacrylamide gel electrophoresis and transferred onto a polyvinylidene difluoride membrane. Then the membrane was incubated with primary anti-Runx2, and anti-b-actin antibodies (1 : 1000; Santa Cruz, Santa Cruz, USA) for 16 h at 48C. Horseradish peroxidase-conjugated anti-mouse IgG (Santa Cruz) antibodies were used as secondary antibodies. The signal was detected by the Lumi-ECL test system (Xitang, Shanghai, China). b-Actin was used as an internal control and the relative protein expression was analyzed by Quantity One 4.52 software(Bio-Rad, Hercules, USA).
Prediction of microRNA targets
The sequence of mature human miR-204 was obtained from the microRNA database (http://www.mirbase.org). The target site in the 3 0 -UTR of Runx2 gene that miR-204 bound to was predicted using the TargetScanHuman 6.2 and PicTar in the website.
Plasmid construction
The pGL3 control vector was used (Promega, Madison, USA) as our backbone vector. The 3 0 -UTR sequence of gene Runx2 was amplified from the human genome by using the Touchdown method. PCR products were cloned into BglII/AatII modified PGL3 control report vectors. To generate mutated Runx2-3 0 -UTR plasmid, a site-directed mutagenesis technique was used.
Luciferase assay
For the firefly luciferase assay, 293 T cells in six-plate well were transfected with 1 mg of the luciferase reporter vector and 1 mg of the pcDNA3.1-204 vector using Lipofectamine 
Transfection of miRNA into AA BMSCs
The synthetic miR-204 mimic and inhibitor were purchased from Qiagen. The synthetics were transfected into AA BMSCs using HiPerFect Transfection Agent (Qiagen) according to the manufacturer's instruction. The transfection mixture containing miRNA mimics and inhibitors at a final concentration of 50 nM was incubated with cells under cell culture conditions for 72 h. Then, the culture medium was replaced by fresh expansion medium.
Statistical analysis
Each experiment was repeated three times and the average value was calculated. Statistical analysis was carried out using an independent unpaired and paired Student's t-test, and P , 0.05 was considered to be statistically significant.
Results
Morphology and immunophenotypic profiles were indistinguishable between normal and AA BMSCs In vitro, BMSCs from AA patients and control group shared a similar spindle-shaped morphology (Fig. 1) . Immunophenotypic results showed that BMSCs from both groups exhibited a consistent immunophenotypic profile which was negative for CD45 and CD34, and positive for CD105, CD73, and CD44 ( Table 2) . No significant difference in surface markers was detected.
AA BMSCs showed abnormal differentiation potential that can be corrected by ATO treatment Under osteogenic induction condition, AA BMSCs showed fewer and smaller nodes than the control group by Alizarin red staining, indicating less efficient differentiation. When Table 1 . Primer sequences used in this study
Gene
Sequence
F, forward primer; R, reverse primer.
AA BMSCs were treated with 1 mM ATO for 48 h, there was no visible effect on cell growth. After treatment, the mineralization nodes of AA BMSCs appeared to be larger than AA BMSCs without treatment ( Fig. 2A) . These data suggested that ATO can at least partially rescue the osteogenic induction defect in AA BMSCs.
Under adipogenic induction condition, the droplets of fat of AA BMSCs were more and larger than the control group by Oil red O staining, indicating more efficient differentiation towards the adipogenic fate. When AA BMSCs were treated with 1 mM ATO for 48 h, the size of fat droplets was significantly decreased (Fig. 2B) . Quantification of dye content of Alizarin red stain in the osteogenic cultures and Oil red O stain in the adipogenic cultures confirmed the histochemical observations (Fig. 2C,D) . Our results showed that under the culture condition, AA BMSCs are more prone to adipocyte lineage induction, yet more reluctant to differentiate towards osteoblasts compared with healthy controls. Moreover, this abnormal differentiation potency can be at least partially corrected by ATO treatment.
Transcription factor Runx2 was typically induced when osteogenic differentiation took place During the time course of BMSC differentiation into osteogenic lineage, real-time PCR analysis was used to measure the expression of Runx2 gene on days 0, 7, 14, and 21. The expression of Runx2 in the AA BMSC group was significantly lower than that in the control group on days 7, 14, and 21. When AA BMSCs were treated with 1 mM ATO for 48 h, the expression of Runx2 gene was partially rescued, which is consistent with the staining evaluation results (Fig. 3A) .
LPL and PPARg genes are markers for adipogenic differentiation. Thus, their expressions were measured during the time course of BMSCs differentiating into adipogenic lineage. The expression of LPL gene was significantly higher in AA BMSCs than that in the normal BMSC group at all stages. After AA BMSCs were treated with 1 mM ATO for 48 h, the expression of LPL gene was reduced. The expression level of PPARg gene showed a similar trend to that of the LPL gene at all measures (Fig. 3B) . Altogether, our data suggested that AA BMSCs show abnormal differentiation potential towards adipogenic lineage, and ATO treatment can partially restore the balance.
MiR-204 bound to 3
0 -UTR of Runx2 mRNA to inhibit Runx2 expression According to the prediction by TargetScan and PicTar, miR-204, miR-135, miR-23, miR-466, miR-433, and miR-467 could potentially bind 3 0 -UTR of Runx2 mRNA through multiple binding sites. It was shown that among them only miR-204 expression was significantly increased during the adipocyte differentiation [17] . Consistent with published data, we found that when AA BMSCs were induced into adipocytes, the expression of miR-204 was significantly induced on day 14 (P , 0.01) (Fig. 4A) . Runx2 mRNA level was only slightly decreased (P . 0.05) (Fig. 4B) , whereas Runx2 protein level was dramatically reduced compared with undifferentiated cells (Fig. 4C) .
MiRNAs play their role through binding the 3 0 -UTR of target mRNA. Thus, we hypothesized that miR-204 binding to the 3 0 -UTR of Runx2 mRNA would decrease Runx2 protein level and prevent cells from differentiation towards the osteogenic lineage. Luciferase reporter assay was conducted. After co-transfecting luciferase construct Runx2-WT (wild-type), Runx2-MUT (mutated), Runx2-PC ( positive control), and NTC (non-template control) with miR-204 mimics, the cells were harvested and analyzed for dual luciferase activity. Our results showed that the Renilla luciferase activity for Runx2-WT-transfected cells was significantly lower compared with that in the Runx2-PC co-transfected cells. In addition, the seed region mutation abolished the inhibitory effect of miR-204 mimics (Fig. 5) . These results revealed that miR-204 can regulate Runx2 protein expression by partially complementary binding to the 3 0 -UTR of Runx2 mRNA.
To investigate whether the over-expression of miR-204 can inhibit endogenous Runx2 protein expression, we transfected chemically synthesized miR-204 mimics into AA BMSCs. Western blot analysis showed that Runx2 protein levels were significantly reduced. To achieve the loss of function of miR-204, we transfected miR-204 inhibitor into AA BMSCs. Western blot analysis showed that Runx2 protein levels were significantly increased (Fig. 6) . Together, our results indicated that miR-204 could directly regulate Runx2 expression in AA BMSCs.
MiR-204 promoted adipocyte differentiation and inhibited osteoblast differentiation Runx2 is a key transcription factor in regulating osteogenesis and chondrogenesis [21 -23] . In order to investigate whether miR-204 influence adipocyte differentiation and osteoblast differentiation, we transfected chemically synthesized miR-204 mimics or inhibitors into AA BMSCs, and then conducted the adipogenic and osteogenic induction.
The expression of BMP2 was measured on day 12 upon osteogenic induction. Our Results showed that the expression of BMP2 in miR-204 over-expressed cells was much lower than that in AA BMSCs without adding miR-204 (P , 0.05), while the expression of BMP2 in miR-204 loss-of-function cells increased by at least 5.1 times compared with that in AA BMSCs without transfection (P , 0.05). When all these cells were treated with 1 mM ATO for 48 h, the expression of BMP2 was slightly increased after 12-day induction compared with miR-204 over-expressed cells and miR-204 loss-of-function cells. The expression level of Runx2 gene showed a similar trend to that of the BMP2 gene (Fig. 7A) .
PPARg mRNA level was measured on day 12 upon adipogenic induction. Our results showed that the expression of PPARg in miR-204 over-expressed cells was increased by at least four times compared with that in AA BMSCs without adding miR-204 (P , 0.05). Conversely, the expression of PPARg in miR-204 loss-of-function cells was much lower than that in AA BMSCs without transfection (P , 0.05). When all these transfected cells were treated with 1 mM ATO for 48 h, the expression of PPARg was slightly decreased after 12-day induction compared with miR-204 overexpressed cells and miR-204 loss-of-function cells (Fig. 7B) . Our results suggested an endogenous function of miR-204 in promoting adipocyte differentiation while inhibiting osteoblast differentiation.
Discussion
AA is characterized by abnormalities of hematopoietic stem cells and the hematopoietic microenvironment, which are caused by altered immune cells and molecules [24, 25] . Altered immune cells directly and indirectly destroy stem/ progenitor cells by secreting a variety of immune molecules into the bone marrow. Those cytokines are likely to play important roles in the recruitment and activation of lymphocytes into cytotoxic effectors for bone marrow hematopoietic target cells in AA. MSCs are important components of bone marrow hematopoietic microenvironment, which are capable of supporting the long-term maintenance and differentiation of hematopoietic stem cells. The dysfunction of MSCs may result in the impairment of hematopoiesis. In our study, we demonstrated the differentiation defects of AA BMSCs. Although AA and control group BMSCs shared a similar spindle-shaped morphology and surface marker expression, AA BMSCs grew more slowly, smaller in amount than the control group.
MSCs are non-hematopoietic progenitor cells first isolated from bone marrow, which show a stromal nature by providing extracellular matrix components, cytokines, and growth factors to facilitate the maintenance of stem cell niches. Marrow stromal cells, including fibroblasts, osteoblasts, endothelial cells, and adipocytes, derive from MSCs and provide an appropriate scaffold and complex network of adhesion molecules, cytokines, and extracellular matrix proteins [26 -29] . It is clear that osteoblasts and adipocytes originate from the common precursors known as MSCs in the bone marrow, through the activation of specific transcription factors Runx2 and PPARg. The activation of Runx2 and the down-regulation of PPARg direct MSCs into osteogenic lineage and reciprocal transcriptional event leads to adipogenic lineage [30] . In this study, we demonstrated that AA BMSCs are more prone to adipocyte lineage induction, yet more reluctant to differentiate towards osteoblasts compared with healthy controls. Real-time PCR analysis also showed that LPL and transcription factor PPARg expression are significantly increased, while Runx2 expression significantly reduced compared with normal BMSCs Aging has a possible effect on the proportion of fatty marrow. In neonatal mammals, adipocytes are absent in the bone marrow, which are primarily haematopoietic at this stage. However, along with the growth of the age, the number of adipocytes increases rapidly, resulting in the appearance of fatty marrow. In adults, adipocytes account for most of medullary cavity. With aging, the proportion of BMSCs differentiated into adipogenic lineage increases, whereas the proportion of BMSCs differentiated into osteogenic lineage decreases. In our study, the two groups of patients are of similar age, thus the influence of age on BMSC differentiation potential can be ruled out [30] .
Previous studies have suggested that bone marrow adipocytes are predominantly negative regulators of the bone marrow microenvironment [31] and are less supportive to hematopoiesis than those of other cell types derived from mesenchymal progenitors, such as osteoblasts [32] . Moreover, the abolishment of the bone marrow adipocyte compartment will induce osteogenesis [31] , which provides a more supportive environment for hematopoietic reconstitution. Osteoblasts support hematopoiesis via producing hematopoietic growth factors [33] and high levels of the Notch ligand jagged 1 to maintain HSCs with Notch1 activation in vivo [34] . Taken these into consideration, regulating the balance of BMSCs osteogenic and adipogenic differentiation may be a potential therapeutic strategy for AA.
ATO is used to treat a variety of malignant blood diseases and to achieve remarkable clinical responses, by inducing differentiation, apoptosis, and modulating DNA synthesis of tumor cells. It has been shown that ATO has a dramatic impact on the differentiation of keratinocytes and adipocytes [35, 36] . Treating hMSCs with ATO could inhibit PPARg, which plays a critical role in regulating most of adipocytespecific genes [37] . Subsequent tests confirmed that ATO suppressed adipogenic differentiation by down-regulating the expression of PPARg in the cellular environment of C3H 10T1/ 2 cells [38] . ATO inhibits adipogenic and promotes osteogenic differentiation in hMSCs by inhibiting PPARg and C/ EBPa [11] . In this study, we showed that when AA BMSCs were treated with ATO for 48 h, the expression of LPL and PPARg significantly decreased, whereas Runx2 increasingly expressed. Therefore, we concluded that ATO inhibits adipogenic differentiation but promotes osteogenic differentiation. ATO may be valuable in the treatment of diseases that are characterized by excessive adipogenesis and insufficient bone formation. Our previous clinical studies have revealed the efficacy of ATO in patients with severe AA (SAA) and AA.
Several studies have demonstrated that miRNAs are involved in stem cell maintenance and differentiation [16] , playing critical roles in the function of stem cells [39] . In this study, luciferase reporter assay proved that miR-204 could potentially bind to 3 0 -UTR of Runx2 mRNA. Runx2 has been identified as a key transcription factor for osteoblastic differentiation of precursor cells. Runx2 over-expression in bone marrow stromal cells accelerates bone formation in critical-sized femoral defects [40] . Our study showed that upon over-expression or inhibition of miR-204 in MSCs, the expression of Runx2 was decreased or increased, respectively, demonstrating that miR-204 acts as a negative regulator of Runx2 in inhibiting osteoblastic differentiation and promoting adipogenesis of MSCs [17, 41] . ATO treatment did not exert a significant effect on Runx2 expression upon miR-204 manipulation.
BMSCs derived from AA exhibit differentiation defect and these alterations may be important in understanding pathogenesis of the disease. The fact that ATO inhibits adipogenic differentiation but promotes osteogenic differentiation indicate that ATO may be valuable in the treatment of AA. MiR-204 inhibits osteogenic differentiation and promotes the adipogenesis of BMSCs by directly suppressing Runx2. No obvious synergism and antagonism were detected during the combination of miR-204 and ATO. Although the small sample size might limit our current study, it is still promising that ATO and miRNA may provide a novel therapy for diseases with imbalance of osteogenic and adipogenic differentiation.
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